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The patched (PTCH) mutation rate in nevoid basal cell carcinoma syndrome (NBCCS) reported in various studies ranges from 40 to
80%. However, few studies have investigated the role of PTCH in clinical conditions suggesting an inherited predisposition to basal cell
carcinoma (BCC), although it has been suggested that PTCH polymorphisms could predispose to multiple BCC (MBCC). In this study,
we therefore performed an exhaustive analysis of PTCH (mutations detection and deletion analysis) in 17 patients with the full
complement of criteria for NBCCS (14 sporadic and three familial cases), and in 48 patients suspected of having a genetic
predisposition to BCC (MBCC and/or age at diagnosis p40 years and/or familial BCC). Eleven new germline alterations of the PTCH
gene were characterised in 12 out of 17 patients harbouring the full complement of criteria for the syndrome (70%). These were
frameshift mutations in five patients, nonsense mutations in five patients, a small inframe deletion in one patient, and a large germline
deletion in another patient. Only one missense mutation (G774R) was found, and this was in a patient affected with MBCC, but
without any other NBCCS criterion. We therefore suggest that patients harbouring the full complement of NBCCS criteria should as
a priority be screened for PTCH mutations by sequencing, followed by a deletion analysis if no mutation is detected. In other clinical
situations that suggest genetic predisposition to BCC, germline mutations of PTCH are not common.
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Nevoid basal cell carcinoma syndrome (NBCCS, or Gorlin’s
syndrome) is an autosomal dominant syndrome predisposing to
basal cell carcinomas (BCCs) and numerous developmental
abnormalities (Gorlin, 2004). The prevalence is estimated at one
per 57000 (Evans et al, 1991); approximately 0.4% of all cases of
BCC and 2% of BCC patients under 45 years of age are affected by
NBCCS (Farndon et al, 1992).
NBCCS has been linked to germline mutations in the human
homologue of the Drosophila segment polarity gene patched
(PTCH) (Hahn et al, 1996; Johnson et al, 1996), and the rate of
neomutation is high (Shanley et al, 1994). The PTCH mutation
frequency in NBCCS patients reported varies considerably in the
different studies, ranging from 40 to 80% (Kimonis et al, 2004;
Marsh et al, 2005).
The PTCH gene consists of 23 exons, and encodes a 1447-amino-
acid integral membrane protein, with 12 transmembrane regions,
two extracellular loops, and a putative sterol-sensing domain.
Most PTCH germline mutations are predicted to lead to pre-
mature truncation of the Ptc1 protein, and assumed to represent
null PTCH alleles (Wicking and Bale, 1997), suggesting that
many aspects of the phenotype apart from BCC result from
haploinsufficiency. Tumours in NBCCS patients are likely to arise
when the remaining PTCH allele is inactivated, which would
be consistent with PTCH acting as a tumour suppressor gene
(Gailani et al, 1992).
In addition, deletions of interstitial chromosome 9q have been
identified in some NBCCS patients (Olivieri et al, 2003; Haniffa
et al, 2004; Boonen et al, 2005).
One problem that arises is the possibility of a misdiagnosis of
NBCCS, because of the complex phenotype of this syndrome.
Various clinical and radiological criteria have been used to
diagnose NBCCS; these are categorised as major and minor
criteria. Nevoid basal cell carcinoma syndrome is considered to
be certain when at least two of the four major criteria are present
(multiple BCC (MBCCs), palmar and plantar epidermal pits,
jaw keratocysts, and cerebral calcification) (Shanley et al, 1994).
Patients may also display many other clinical features that are
classified as minor criteria (Table 1) (Lo Muzio et al, 1999). Received 22 March 2006; revised 6 July 2006; accepted 7 July 2006
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allelic variation of PTCH could also influence susceptibility
to BCC (Strange et al, 2004a,b; Asplund et al, 2005). In particular,
some PTCH haplotypes, including polymorphisms in
exon 23 (c.3944C), intron 15 (G
2560þ9), or exon 12 (c.1686C),
seem to have a potentially protective effect against BCC (Strange
et al, 2004a,b).
The goal of this study was to search for PTCH germline
abnormalities both in patients harbouring all the criteria for
NBCCS and in those clinically suspected of having a genetic
predisposition towards BCC (MBCC and/or BCC while under 40
years of age and/or familial BCC).
PATIENTS AND METHODS
Selection of patients
This study was performed from 2003 to January 2005. Patients
were enrolled at the Saint Louis (60%), Ambroise Pare ´ (25%),
Bichat-Claude Bernard (5%), Tarnier (5%), and Henri Mondor
(5%) hospitals, all of which are located in or near the city of Paris
(France). Sixty-five patients were prospectively enrolled in the
study, 10% of whom were newly diagnosed cases. Two different
categories of patients were studied:
(1) Patients affected by the typical NBCCS (17 index cases: three
familial and 14 sporadic) who displayed at least two of the
major criteria (MBCC, palmo-plantar pits, cerebral calcifica-
tions, odontogenic keratocysts) or one major criterion plus at
least two minor criteria as defined by Shanley et al (1994). In
addition, seven additional NBCCS patients from the three
enrolled families were also studied.
(2) Patients strongly suspected of having a genetic predisposition
towards BCC (48 cases), characterised by either (i) MBCCs
(35 cases), defined as the presence of at least two BCCs
in the same patient confirmed by pathology reports, and/or
(ii) BCC in patients under 40 years of age (28 cases)
and/or (iii) familial BCC (10 cases), defined as the presence
of at least two BCC cases in first- or second-degree
relatives (all cases confirmed by pathology reports). For
familial BCC cases, only the proband was enrolled. To
exclude the presence of NBCCS features in this
‘BCC-predisposed’ non-NBCCS group, a careful clinical
exam was realised to search for BCC, pits on palm and soles,
facial, ocular, and limbs abnormalities. In addition, dental
and crane X-rays were also performed in order to verify the
absence of odontogenic keratocysts and intracranial calcifica-
tions.
Written informed consent, agreeing to peripheral blood
sampling and genetic analysis, was obtained from each patient
enrolled in the study. Genomic DNA was isolated from peripheral
blood leucocytes of all the participants by routine methods (Miller
et al, 1988).
PTCH sequencing
The 23 exons of the PTCH coding sequence were amplified using
23 primer pairs (Table 2). PCR conditions included 35 denaturing
cycles at 951C for 30s, annealing at 601C for 30s, elongation at
721C for 45s for exons 1 and 4; and 35 denaturing cycles at 961C
for 30s, annealing at 631C for 30s, elongation at 721C for 1min for
exons 5–23. Sequence analysis was performed on an ABI-Prism
3100 automated DNA sequencer using 10ng PCR purified products
and Big-Dye Terminator Cycle Sequencing kits (Perkin Elmer,
Courtaboeuf cedex, France), according to the manufacturer’s
instructions. The functionality of the nonsynonymous variant
was predicted using the Polyphen and SIFT informatics program
(http://tux.EMBL-Heidelberg.DE/ramensky/; http://blocks.fhcr-
c.org/sift/SIFT_seq_submit2.html).
PTCH deletion analysis
Real-time quantitative PCR Real-time quantitative PCR was
performed using SYBR Green I dye as a fluorescent signal. This
dye binds specifically to the minor groove of double-stranded
DNA, making it possible to detect PCR product formation
(Ginzinger, 2002).
In order to examine both ends of PTCH, two targets were
initially chosen on PTCH exons 1 and 23, and then, to extend the
analysis, two other PTCH targets on exons 4 and 15, respectively,
were also examined (Table 2). Two single-copy sequences were
used as reference sequences: MYH9, mapping at 22q13.1, and Rb,
mapping at 13q. Five microlitres of DNA was added to the PCR
reaction mixture containing 1  SYBR Green buffer (Applied
Biosystems, Courtaboeuf cedex, France), 300nM forward and
reverse primers, 5mM MgCl2 (3mM for 8q11 SST), 200mM dNTP,
and 0.6U of AmpliTaq Gold (Applied Biosystems) in a final
volume of 25ml.
Each series of PCR reactions included two negative controls,
containing water in place of DNA, and a five-point standard curve.
The standard curve was plotted using serial dilutions of normal
PBMC in Tris (10mM)–EDTA (1mM) buffer, ranging from 10 to
0.02ngml
 1 (corresponding to 50–0.1ng of DNA analysed per
well). The same dilutions were used for all targets and reference
sequences. PCR was performed on the ABI PRISM 7700 Sequence
detector system (Applied Biosystems). All analyses were performed
in duplicate. The PCR amplification profile was as follows: initial
denaturing at 951C for 10min, followed by 40 denaturing cycles at
951C for 10s, and a combined annealing and extension step at 651C
for 1min. Detection of the fluorescent product was carried out at
the end of the extension period. To confirm amplification
specificity, the PCR products from each primer pair were subjected
to a melting curve analysis, and subsequent agarose gel electro-
phoresis. The concentration of each gene was calculated based on
the appropriate calibration curve. Relative copy numbers of PTCH
were then obtained by calculating the ratio of the result obtained
for each target to the MYH9 and Rb value. The normalised ratio of
each target on MYH9 and Rb was expected to be close to 1, if no
deletion had occurred.
Microsatellite analysis
Two microsatellite markers were studied: (i) a CGG repeat
localised in the 50UTR, which was genotyped by sequencing PTCH
exon 1, and (ii) a CA repeat localised in intron 2 (Aboulkassim
et al, 2003), which was genotyped by migration of the fluorescent-
Table 1 NBCCS minor criteria
NBCCS minor criteria
Congenital skeletal anomaly: bifid, fused, splayed, or missing rib, bifid, wedged or
fused vertebra, cyphoscoliosis, brachydactyly, short fourth metacarpal, short thumb
terminal phalanx
Macrocephaly, frontal bossing, prognathism
Congenital mouth malformation: cleft lip or palate, coarse face, polydactyly
Eye anomaly: strabismus, hyperthelorism, cataract, coloboma, microphtalmia
Cardiac or ovarian fibroma
Medulloblastoma
Lymphomesenteric cysts, congenital lung cyst
Mental retardation
NBCCS¼nevoid basal cell carcinoma syndrome.
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Biosystems).
Multiplex ligation-dependent probe amplification
PTCH deletion was also investigated by multiplex ligation-
dependent probe amplification (MLPA), a quantitative, multiplex
PCR method, as described previously (Gille et al, 2002). Multiplex
ligation-dependent probe amplification was used to determine the
relative copy number of each of the 23 PTCH exons, and was
performed using an available commercial kit (SALSA MLPA KIT
P067 PTCH, mrc-Holland).
RESULTS
Seventeen patients were considered to have NBCCS, on the basis of
the presence of two major criteria, or of one major criterion plus
two or more minor criteria. Three were nonrelated familial cases,
and 14 were sporadic cases. The three families had, respectively,
four, three, and two NBCCS patients, all first-degree related.
Table 2 PTCH PCR primers
Exon number Primer name Primer sequence (50-30)
Sequencing primers
1 PTCH Ex 01F TGG AAG GCG CAG GGT CTG ACT
PTCH Ex 01 R CGA TCC CAA AGA GTT AGA GGA
2 PTCH Ex 02F CTG CGG CCC GGC TTT ATG AC
PTCH Ex 02R GTG TGC GCT GGC GAA TAT CTC TAT C
3 PTCH Ex 03F ACT GCT CAC ACA TCA GCC AGT CTC AT
PTCH Ex 03R GCA TTT CCA GGG CAA CTT CAT TTA CTA
4–5 PTCH Ex 04–05F GCT GGG TCT CTA CTT GGC AAA AGC
PTCH Ex 04–05R CCC GAC TAT TCA CTC AAA AAA TGC ACA
6 PTCH Ex 06F ATT TGT TTT GAT GCC AGA GTC CCA GA
PTCH Ex 06R GGC TAA TGG GAG GTG TAT GGC AAA TC
7 PTCH Ex 07F AAG ATT TGC CAT ACA CCT CCC ATT AGC
PTCH Ex 07R AAT TCC CCA CAA GGT GCT TTT TCA A
8 PTCH Ex 08F GGA AAC ATG TGC TCA CAG AGA AGG AAA
PTCH Ex 08R TCC CAT CAA GTT CCC AGA ATT GCA
9 PTCH Ex 09F CCC TGC CCT GGA ATC ACG TAG AAC
PTCH Ex 09R GAA GCA GGA GCA GTC ATG GAA AAG TAA
10 PTCH Ex 10F TTT GCC GTT TGC CTA CCT TTG ACT C
PTCH Ex 10R CGG TGA GAA GGA CAC ACA GCA CAC
11 PTCH Ex 11F AGG TGC TGG TGG CAG AGT CCT AAC TA
PTCH Ex 11R GCA GCC AGT GAC ACA TCA TCT GAC AT
12 PTCH Ex 12F CTG CCA CGT ATC TGC TCA CAC AGT C
PTCH Ex 12R CAC CCA GTT AAA CAG AGC CTC AAA CAC
13 PTCH Ex 13F CAC GGT TTC AAA TGC TTC AAG AGG A
PTCH Ex 13R CAA ACC CCG TTA CCC ACA TTC CTT
14 PTCH Ex 14F CAG GCG ATG AAC CAG GTG ATG TTA T
PTCH Ex 14R GAA GCA ATC TGA TGA ACT CCA AAG GTT
15 PTCH Ex 15F TTG TCC AGG AAG AGT CAG TGG TGC TC
PTCH Ex 15R GTT GAA GCT GAA CAC GCA AAA GAC C
16 PTCH Ex 16F CCC TGC CCT GCT CAG TCT CCT C
PTCH Ex 16R CTG GCA TGA GGT CAC ACA ATT AGC TG
17 PTCH Ex 17F GCC AGT GAT TGC ATC CTC CGA TAA
PTCH Ex 17R CCA TTA CAC ATC CTC GTC TCC CAG AG
18 PTCH Ex 18F CCT CAC AAA GAA TGA CTG CTG GAA GAT
PTCH Ex 18R CCA GAG GCC CAG ACA TAA ACA AAA CTT
19 PTCH Ex 19F AAG GTT CCC ACT TGG AGA CAA ACA GAG
PTCH Ex 19R TGA ATT AGG CAG TAA AGG CAG TGT CCA
20 PTCH Ex 20F TAC GTC AAC ACC AAA TAT GAC CCA GTG
PTCH Ex 20R TCT GCC TCA GCC TCC CAA GTA GC
21 PTCH Ex 21F TGA ATG TGA ACT GCG GTT GGA TAA CA
PTCH Ex 21R CCA GTA CAC CGA AGA GGA AAA CAG ACA
22 PTCH Ex 22F CCC CTG AAA AAT ACC GTG CTT TGA G
PTCH Ex 22R ATC TGC CTG TGT GAT GTG CTG CTC
23 PTCH Ex 23F GGG TTG ACT GAG TCT TTG GTG AAA CC
PTCH Ex 23R TTG TCC TCC TCT TTG CCT GGC TCT A
Quantitative PCR primer
PTCHqex1F CCA AAG AGT TAG AGG AGG GAA GAG AAA GT
PTCHqex1R CTA TCT GCA CCG GCC CAG CTA C
PTCHqex4F GCT GGG TCT CTA CTT GGC AAA AGC
PTCHqex4R TTT CCA CTG CCT AAT AAA ATG AAA AGC
PTCHqex15F AAG AAA ACA AAC AGC TTC CCA AAA TGT
PTCHqex15R GTT GAA GCT GAA CAC GCA AAA GAC C
PTCHqex23F TCC AGC CAG CCG TGT CAG AGA
PTCHqex23R TTC CAC CCA CAA AAG AAA AGC CTG T
NBCCS¼nevoid basal cell carcinoma syndrome; PTCH¼patched.
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patients with two major criteria, seven patients with three
major criteria, and two patients with all four criteria). Four
NBCCS patients had only one major criterion plus two, four or five
minor criteria. The frequencies of the major criteria were as
follows: MBCC (88%), palmo-plantar pits (78%), odontogenic
keratocysts (70%), and cerebral calcifications (57%). The most
frequent ‘minor’ criteria were macrocephaly (70%), epidermal
cysts (60%), scoliosis (60%), hypertelorism (50%), and strabism
(36%). The median age at the first BCC in this NBCCS group was
27 years.
Forty-eight patients suspected of being predisposed to BCC were
characterised by either (i) the occurrence of MBCC (35 cases)
and/or (ii) the occurrence of BCC before the age of 40 years (28
cases), and/or (iii) the presence of familial BCC (10 cases), defined
as the presence of at least two BCC cases in first- or second-degree
relatives. The median age at the first BCC in this group was
42 years.
PTCH mutations were identified in 12 out of 17 patients
harbouring the full complement of criteria for NBCCS. These were
frameshift mutations in five patients, nonsense mutations in five
patients, and one in frame deletion in one patient (see Table 3). An
identical, nonsense mutation, W129X, was characterised in two
unrelated patients. PTCH mutations were detected in all three
familial cases, and were shown to segregate with the disease in the
families, as they were detected in all the seven relatives affected by
NBCCS (Table 3).
In addition, a large germline deletion was detected in another
typical NBCCS patient. Quantitative PCR analysis showed that
three of the four exons examined (4, 15, 23) were deleted, whereas
the first exon was not. As the patient was heterozygous for a
microsatellite localised in intron 2, this means that the deletion
must begin after exon 2 of PTCH. These results were confirmed by
MLPA, with a 50% reduction in signal intensity from exons 5 to 23,
whereas exon 3 was normal. As the MLPA kit does not explore
exon 4, both results are concordant and show the presence of a
large PTCH deletion including exons 4–23. PTCH deletions were
also looked for in the five remaining NBCCS patients who did not
harbour any PTCH mutation, but none was found. To summarise,
therefore, germline mutations or deletions of PTCH were present
in 70% of NBCCS patients.
In contrast, in the BCC group without any other criterion for
NBCCS, only one missense variant, G774R, was found in a patient
affected with MBCC. This patient had five different BCCs, all
localised in the head and neck region, the first BCC being
diagnosed at the age of 46 years. This variant localised in the
putative fourth extracellular domain, and is predicted to be
damaging by the SNP prediction programs Polyphen and SIFT
(http://tux.embl-heidelberg.de/ramensky/; http://blocks.fhcrc.org/
sift/SIFT.html). No large deletions of PTCH were observed by
real-time PCR or MLPA in the remaining patients with a suspected
genetic predisposition to BCC.
DISCUSSION
In this study, we identified PTCH mutations or deletions in 12 out
of 17 patients with NBCCS (70%). As far as we know, only one
study has been performed in the French population (Boutet et al,
2003). Of the 11 mutations identified in NBCCS patients, 10
resulted in truncation of the PTCH protein owing to frameshifts or
nonsense mutations. This is consistent with the finding that most
(86%) mutations lead to premature termination of the protein
(Wicking et al, 1997; Fujii et al, 2003).
Previously, PTCH mutations have been found in 40–80% of
NBCCS patients (Chidambaram et al, 1996; Wicking et al, 1997;
Boutet et al, 2003). Although our group is quite small, the
exhaustive screening for PTCH exons and flanking intronic regions
by direct sequencing and deletion analysis may have increased the
mutation detection rate.
We identified a large PTCH deletion in a patient harbouring the
typical signs of NBCCS. In all, five patients that share NBCCS
features were previously been reported to carry an interstitial
chromosome 9q deletion identified by cytogenetic analysis
(Shimkets et al, 1996; Sasaki et al, 2000; Haniffa et al, 2004; Midro
et al, 2004). This indicates that large PTCH deletions are not a rare
mechanism of PTCH inactivation, and this possibility should be
investigated if no PTCH mutation is detected.
Despite the exhaustive analysis, no PTCH mutation or large
deletion was found in five of the NBCCS patients. This is likely to
be due to the existence of mutations outside the regions analysed
possibly in introns or regulatory elements. An alternative
hypothesis could be the presence of a somatic mosaicism, or the
existence of mutations in another gene implicated in the sonic
hedgehog pathway, as has been shown to occur in sporadic BCC
(Reifenberger et al, 1998; Xie et al, 1998).
In the group of BCC patients without any other NBCCS
criterion, only one missense mutation (G774R) was found in a
patient with MBCC without any other NBCCS criteria (in
particular, this patient had a normal head circumference, no facial
or ocular abnormalities, and the chest and crane X-rays did not
show any skeletal abnormality or intracranial calcification).
Unfortunately, segregation could not be assessed because his
parents were deceased. Therefore, the significance of this
Table 3 PTCH mutations in NBCCS and MBCC patients
Patient Diagnosis Exon PTCH mutation Effect on protein Familial Segregation
B249 NBCCS 4–23 del Truncated   NA
P270 NBCCS 2 c.385 G4A W129X   NA
B530 NBCCS 15 c.2443–2461 del 18 p. I815N Del (Q816, H817, L818, L819, Y820, D821) + Yes, four cases
B344 NBCCS 15 c.2450 T4A L818X   NA
B370 NBCCS 17 c.2712 C4T Q905X   ND
B395 NBCCS 6 c.922 delG p. A308PfsX323 + Yes, two cases
B401 NBCCS 18 c. 2962 dup TT p. V988LfsX995 + Yes, one case
B419 NBCCS 18 c.3053 G4A W1018X   NA
B420 NBCCS 17 c. 2743 ins CATCATT p. N915Hins7fsX917   NA
P433 NBCCS 2 c.260–265 delTTTA p. F88Ndel4fsX116   NA
B484 NBCCS 2 c.291 insA p. N97KfsX139   NA
B519 NBCCS 2 c.385 G4A W129X   NA
P345 MBCC 15 c.2320 G4A G774R   NA
PCTH mutations are described using the nomenclature system for human gene mutations (den Dunnen and Antonarakis, 2001). MBCC¼multiple basal cell carcinoma;
NA¼not applicable; NBCCS¼nevoid basal cell carcinoma syndrome.
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a functional analysis is performed. However, this could be a
causative mutation, as (i) it is predicted to be damaging by two
bioinformatic programs Polyphen and SIFT and (ii) it was not
reported in any previous study or in the NCBI SNP database. On
the other hand, we cannot exclude the possibility that this could be
a rare polymorphism.
We did not found any other PTCH mutation in this group
(Po0.0001), which indicates that when other NBCCS criteria
are absent, PTCH mutations are rarely involved in predis-
position to BCC. Nevertheless, it remains possible that PTCH
polymorphisms located outside the coding sequence or intron–
exon junctions could influence BCC susceptibility, as has been
suggested by recent publications (Strange et al, 2004a,b; Asplund
et al, 2005).
In conclusion, germline abnormalities (mutations and deletions)
of PTCH are very predominantly observed in patients with the
full criteria for NBCCS. We therefore suggest that patients
harbouring the full complement of NBCCS criteria should, as a
priority, be screened for PTCH mutations by sequencing, followed
by a deletion analysis if no mutation is detected. The finding
of a PTCH mutation confirms the clinical diagnosis of NBCCS,
therefore validating the clinical and radiological diagnostic
criteria of this syndrome. The molecular confirmation of NBCCS
diagnosis permits a better clinical monitoring (in particular,
dermatological), a choice of the rational therapeutic (e.g. avoiding
radiotherapy for treatment of BCCs). Moreover, it makes it
possible to carry out a genetic council in the families concerned,
and to offer the possibility of antenatal diagnosis if the families
wish it.
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